Security
Teva Pharmaceutical Industries Limited · TEVA
TEVANYSEotherCurrentCIK 818686Updated Oct 30, 2026
Name history
TEVA PHARMACEUTICAL INDUSTRIES LIMITED · through Jan 16, 2001
TEVA price & chart
Loading TradingView…
NYSE:TEVA on TradingView ↗About the company
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health.
In the news
Recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
144 filing
144 filing
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 1.01, 2.03, 9.01
Other Events
Items 8.01
Show 5 more recent filings
8-A12B/A filing
25-NSE - filed by NEW YORK STOCK EXCHANGE LLC regarding TEVA PHARMACEUTICAL INDUSTRIES LTD
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
FWP - filed by TEVA PHARMACEUTICAL INDUSTRIES LTD regarding TEVA PHARMACEUTICAL INDUSTRIES LTD
FWP - filed by TEVA PHARMACEUTICAL INDUSTRIES LTD regarding TEVA PHARMACEUTICAL INDUSTRIES LTD
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 39,856,000,000Source | 41,758,000,000Source | 39,857,000,000Source | 40,131,000,000Source | 41,338,000,000Source | 40,040,000,000Source | 38,415,000,000Source | 42,773,000,000Source | 40,748,000,000Source | 39,326,000,000Source | 43,479,000,000Source | 44,006,000,000Source |
| Property, Plant and Equipment, NetUSD | 4,820,000,000Source | 5,672,000,000Source | 3,928,000,000Source | 4,810,000,000Source | 5,573,000,000Source | 3,998,000,000Source | 4,631,000,000Source | 5,618,000,000Source | 4,080,000,000Source | 4,581,000,000Source | 5,750,000,000Source | 5,739,000,000Source |
| GoodwillUSD | 15,945,000,000Source | 16,124,000,000Source | 15,839,000,000Source | 15,949,000,000Source | 16,488,000,000Source | 15,822,000,000Source | 15,477,000,000Source | 17,007,000,000Source | 16,000,000,000Source | 15,147,000,000Source | 17,177,000,000Source | 17,633,000,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 2,203,000,000Source | 3,319,000,000Source | 3,655,000,000Source | 2,161,000,000Source | 2,258,000,000Source | 3,741,000,000Source | 1,697,000,000Source | 2,991,000,000Source | 3,556,000,000Source | 3,300,000,000Source | 3,226,000,000Source | 2,801,000,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 3,810,000,000Source | 3,462,000,000Source | 3,493,000,000Source | 3,564,000,000Source | 3,766,000,000Source | 3,393,000,000Source | 3,384,000,000Source | 3,456,000,000Source | 3,709,000,000Source | 3,059,000,000Source | 3,408,000,000Source | 3,696,000,000Source |
| Inventory, NetUSD | 3,323,000,000Source | 3,959,000,000Source | 3,221,000,000Source | 3,497,000,000Source | 3,927,000,000Source | 3,176,000,000Source | 3,247,000,000Source | 3,949,000,000Source | 3,179,000,000Source | 3,007,000,000Source | 4,021,000,000Source | 3,833,000,000Source |
| Assets, CurrentUSD | 12,736,000,000Source | 12,314,000,000Source | 13,760,000,000Source | 12,620,000,000Source | 11,632,000,000Source | 13,710,000,000Source | 11,528,000,000Source | 12,297,000,000Source | 13,946,000,000Source | 12,552,000,000Source | 12,485,000,000Source | 12,051,000,000Source |
| Operating Lease, Right-of-Use AssetUSD | 342,000,000Source | 364,000,000Source | 333,000,000Source | 358,000,000Source | 358,000,000Source | 335,000,000Source | 363,000,000Source | 364,000,000Source | 345,000,000Source | 367,000,000Source | 397,000,000Source | 419,000,000Source |
| Other Assets, NoncurrentUSD | 444,000,000Source | 459,000,000Source | 387,000,000Source | 470,000,000Source | 434,000,000Source | 377,000,000Source | 464,000,000Source | 470,000,000Source | 405,000,000Source | 462,000,000Source | 470,000,000Source | 441,000,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 32,602,000,000Source | 35,375,000,000Source | 32,100,000,000Source | 33,297,000,000Source | 34,774,000,000Source | 31,809,000,000Source | 32,146,000,000Source | 35,230,000,000Source | 32,834,000,000Source | 33,606,000,000Source | 35,353,000,000Source | 35,315,000,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 58,000,000Source | 58,000,000Source | 59,000,000Source | 58,000,000Source | 58,000,000Source | 59,000,000Source | 58,000,000Source | 58,000,000Source | 58,000,000Source | 58,000,000Source | 57,000,000Source | 57,000,000Source |
| Additional Paid in CapitalUSD | 28,038,000,000Source | 27,860,000,000Source | 28,256,000,000Source | 28,003,000,000Source | 27,829,000,000Source | 28,203,000,000Source | 27,965,000,000Source | 27,796,000,000Source | 28,133,000,000Source | 27,764,000,000Source | 27,807,000,000Source | 27,688,000,000Source |
| Retained Earnings (Accumulated Deficit)USD | -14,243,000,000Source | -14,956,000,000Source | -13,969,000,000Source | -14,676,000,000Source | -14,519,000,000Source | -13,394,000,000Source | -14,958,000,000Source | -13,673,000,000Source | -13,762,000,000Source | -15,173,000,000Source | -13,534,000,000Source | -12,882,000,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -2,475,000,000Source | -2,769,000,000Source | -2,465,000,000Source | -2,431,000,000Source | -2,881,000,000Source | -2,512,000,000Source | -2,675,000,000Source | -2,775,000,000Source | -2,391,000,000Source | -3,148,000,000Source | -2,697,000,000Source | -2,838,000,000Source |
| Stockholders' Equity Attributable to ParentUSD | 7,250,000,000Source | 6,065,000,000Source | 7,753,000,000Source | 6,827,000,000Source | 6,359,000,000Source | 8,228,000,000Source | 6,262,000,000Source | 7,278,000,000Source | 7,910,000,000Source | 5,373,000,000Source | 7,506,000,000Source | 7,897,000,000Source |
| Liabilities and EquityUSD | 39,856,000,000Source | 41,758,000,000Source | 39,857,000,000Source | 40,131,000,000Source | 41,338,000,000Source | 40,040,000,000Source | 38,415,000,000Source | 42,773,000,000Source | 40,748,000,000Source | 39,326,000,000Source | 43,479,000,000Source | 44,006,000,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 11,491,000,000Source | 13,797,000,000Source | 15,646,000,000Source | 11,861,000,000Source | 13,037,000,000Source | 13,532,000,000Source | 11,157,000,000Source | 13,792,000,000Source | 13,456,000,000Source | 12,796,000,000Source | 12,247,000,000Source | 11,469,000,000Source |
| Operating Lease, Liability, CurrentUSD | — | — | — | — | — | — | — | — | 288,000,000Source | 296,000,000Source | 320,000,000Source | 349,000,000Source |
| Accounts Payable, CurrentUSD | — | — | — | — | — | — | — | — | 225,000,000Source | 158,000,000Source | — | — |
| Operating Lease, Liability, NoncurrentUSD | 283,000,000Source | 295,000,000Source | 282,000,000Source | 296,000,000Source | 281,000,000Source | 280,000,000Source | 288,000,000Source | 294,000,000Source | 288,000,000Source | 296,000,000Source | 320,000,000Source | 349,000,000Source |
| Other Liabilities, NoncurrentUSD | 3,664,000,000Source | 4,344,000,000Source | 3,791,000,000Source | 3,938,000,000Source | 4,356,000,000Source | 3,709,000,000Source | 4,011,000,000Source | 3,991,000,000Source | 3,808,000,000Source | 4,028,000,000Source | 4,019,000,000Source | 3,847,000,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 4,000,000Source | 319,000,000Source | 4,000,000Source | 7,000,000Source | 204,000,000Source | 4,000,000Source | 7,000,000Source | 265,000,000Source | 4,000,000Source | 7,000,000Source | 620,000,000Source | 794,000,000Source |
| Additional Financial Items | ||||||||||||
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | — | — | — | -905,000,000Source |
| Long-term Debt, Current MaturitiesUSD | 1,000,000Source | 2,557,000,000Source | 4,500,000,000Source | 441,000,000Source | 2,071,000,000Source | 2,600,000,000Source | 398,000,000Source | 3,037,000,000Source | 1,798,000,000Source | 1,758,000,000Source | 1,649,000,000Source | 2,086,000,000Source |
| Redeemable Noncontrolling Interest, Equity, Carrying AmountUSD | 0Source | — | — | 0Source | — | — | 0Source | — | 0Source | 340,000,000Source | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | 434,000,000Source | -390,000,000Source | -575,000,000Source | 283,000,000Source | 369,000,000Source | 220,000,000Source | 1,418,000,000Source | -1,959,000,000Source | -615,000,000Source | -2,406,000,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 34,000,000Source | 29,000,000Source | 40,000,000Source | 38,000,000Source | 43,000,000Source | 34,000,000Source | 157,000,000Source | 123,000,000Source | 121,000,000Source | 124,000,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in InventoriesUSD | — | — | — | — | -59,000,000Source | -61,000,000Source | -93,000,000Source | -120,000,000Source | 152,000,000Source | 166,000,000Source | -147,000,000Source | -163,000,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | -418,000,000Source | -340,000,000Source | -1,068,000,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | 369,000,000Source | 693,000,000Source | 411,000,000Source | 227,000,000Source | -40,000,000Source | -105,000,000Source | 1,649,000,000Source | 1,247,000,000Source | 1,368,000,000Source | 1,590,000,000Source |
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | 0Source | 0Source | — | 0Source | — | 0Source | 0Source | 15,000,000Source | 0Source | 7,000,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | 135,000,000Source | 268,000,000Source | -491,000,000Source | 236,000,000Source | 229,000,000Source | 201,000,000Source | 737,000,000Source | 792,000,000Source | 968,000,000Source | 656,000,000Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | — | — | -2,000,000Source | 0Source | 4,000,000Source | -3,000,000Source | -1,000,000Source | 0Source | -5,000,000Source | -2,000,000Source | 5,000,000Source | 0Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | — | — | 548,000,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | -453,000,000Source | 0Source | -1,000,000Source | 6,000,000Source | 13,000,000Source | -1,744,000,000Source | -2,151,000,000Source | -1,791,000,000Source | -1,913,000,000Source | -1,487,000,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | — | — | -2,000,000Source | 0Source | -1,000,000Source | 1,000,000Source | 36,000,000Source | 3,000,000Source | 41,000,000Source | -8,000,000Source | -212,000,000Source | -118,000,000Source |
| Repayments of Long-term DebtUSD | — | — | 444,000,000Source | 0Source | — | 2,300,000,000Source | — | 1,368,000,000Source | 4,112,000,000Source | 1,641,000,000Source | 4,152,000,000Source | 1,369,000,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | 42,000,000Source | 1,061,000,000Source | -86,000,000Source | 464,000,000Source | 185,000,000Source | -1,603,000,000Source | 256,000,000Source | 74,000,000Source | 393,000,000Source | 636,000,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 2,203,000,000Source | 3,319,000,000Source | 3,655,000,000Source | 2,161,000,000Source | 3,741,000,000Source | 1,697,000,000Source | 3,556,000,000Source | 3,300,000,000Source | 3,227,000,000Source | 2,834,000,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 950,000,000Source | 1,004,000,000Source | 1,078,000,000Source | 948,000,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | — | 471,000,000Source | 298,000,000Source | 543,000,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | -9,000,000Source | 100,000,000Source | -5,000,000Source | -5,000,000Source | -17,000,000Source | 45,000,000Source | 21,000,000Source | -174,000,000Source | -30,000,000Source | -123,000,000Source |
| Additional Financial Items | ||||||||||||
| AmortizationUSD | — | — | 144,000,000Source | 146,000,000Source | 139,000,000Source | 148,000,000Source | 137,000,000Source | 145,000,000Source | 581,000,000Source | 588,000,000Source | 616,000,000Source | 732,000,000Source |
| Amortization of Intangible AssetsUSD | — | — | 144,000,000Source | 146,000,000Source | 139,000,000Source | 148,000,000Source | 137,000,000Source | 145,000,000Source | 581,000,000Source | 588,000,000Source | 616,000,000Source | 732,000,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 421,000,000Source | 471,000,000Source | 537,000,000Source | 576,000,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | — | — | — | 25,000,000Source | 18,000,000Source |
| Gain (Loss) on Disposition of BusinessUSD | — | — | — | — | — | — | — | — | -22,000,000Source | 15,000,000Source | 3,000,000Source | 46,000,000Source |
| Gain (Loss) on Disposition of Assets for Financial Service OperationsUSD | — | — | — | — | — | — | — | — | 2,000,000Source | 2,000,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 317,000,000Source | 298,000,000Source | 317,000,000Source | 305,000,000Source | 304,000,000Source | 297,000,000Source | 1,287,000,000Source | 1,161,000,000Source | 1,162,000,000Source | 1,180,000,000Source |
| GoodwillUSD | — | — | 15,945,000,000Source | 16,124,000,000Source | 15,839,000,000Source | 15,949,000,000Source | 15,822,000,000Source | 15,477,000,000Source | 16,000,000,000Source | 15,147,000,000Source | 17,177,000,000Source | 17,633,000,000Source |
| Goodwill, Impairment LossUSD | — | — | 0Source | 600,000,000Source | — | 0Source | — | — | 0Source | 1,280,000,000Source | 700,000,000Source | 2,045,000,000Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | 64,000,000Source | 28,000,000Source | 22,000,000Source | 42,000,000Source | 8,000,000Source | 121,000,000Source | 259,000,000Source | 251,000,000Source | 350,000,000Source | 355,000,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | 2,000,000Source | 3,000,000Source | — | -1,000,000Source | -1,000,000Source | — | 15,000,000Source | 1,000,000Source | 2,000,000Source | 21,000,000Source |
| Income Tax Expense (Benefit)USD | — | — | 214,000,000Source | 69,000,000Source | 121,000,000Source | -78,000,000Source | 67,000,000Source | 74,000,000Source | -180,000,000Source | 676,000,000Source | -7,000,000Source | -638,000,000Source |
| Inventory Write-downUSD | — | — | — | — | — | — | — | — | — | — | — | 4,200,000,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 433,000,000Source | -437,000,000Source | -576,000,000Source | 282,000,000Source | 369,000,000Source | 214,000,000Source | 1,410,000,000Source | -1,639,000,000Source | -559,000,000Source | -2,353,000,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | 1,000,000Source | 47,000,000Source | — | — | — | 6,000,000Source | 7,000,000Source | -320,000,000Source | -56,000,000Source | -53,000,000Source |
| Nonoperating Income (Expense)USD | — | — | -237,000,000Source | -272,000,000Source | -224,000,000Source | -252,000,000Source | -216,000,000Source | -225,000,000Source | -934,000,000Source | -981,000,000Source | -1,057,000,000Source | -966,000,000Source |
| Other Operating Income (Expense), NetUSD | — | — | -7,000,000Source | 21,000,000Source | 19,000,000Source | -4,000,000Source | 9,000,000Source | -5,000,000Source | -18,000,000Source | 14,000,000Source | 49,000,000Source | 107,000,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | 13,000,000Source | — | 26,000,000Source | 3,000,000Source | 47,000,000Source | 19,000,000Source | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 4,480,000,000Source | 4,332,000,000Source | 4,142,000,000Source | 4,176,000,000Source | 3,982,000,000Source | 3,891,000,000Source | 17,258,000,000Source | 16,544,000,000Source | 15,846,000,000Source | 14,925,000,000Source |
| Cost of RevenueUSD | — | — | 2,176,000,000Source | 2,183,000,000Source | 1,989,000,000Source | 2,074,000,000Source | 2,011,000,000Source | 2,014,000,000Source | 8,320,000,000Source | 8,481,000,000Source | 8,200,000,000Source | 7,952,000,000Source |
| Operating Income (Loss)USD | — | — | 882,000,000Source | -51,000,000Source | -231,000,000Source | 455,000,000Source | 652,000,000Source | 519,000,000Source | 2,157,000,000Source | -303,000,000Source | 433,000,000Source | -2,099,000,000Source |
| Income Tax Expense (Benefit)USD | — | — | 214,000,000Source | 69,000,000Source | 121,000,000Source | -78,000,000Source | 67,000,000Source | 74,000,000Source | -180,000,000Source | 676,000,000Source | -7,000,000Source | -638,000,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | 1,000,000Source | 47,000,000Source | — | — | — | 6,000,000Source | 7,000,000Source | -320,000,000Source | -56,000,000Source | -53,000,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 433,000,000Source | -437,000,000Source | -576,000,000Source | 282,000,000Source | 369,000,000Source | 214,000,000Source | 1,410,000,000Source | -1,639,000,000Source | -559,000,000Source | -2,353,000,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 0.38Source | -0.39Source | -0.49Source | 0.25Source | 0.32Source | 0.19Source | 1.23Source | -1.45Source | -0.5Source | -2.12Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0.37Source | -0.39Source | -0.49Source | 0.24Source | 0.31Source | 0.18Source | 1.21Source | -1.45Source | -0.5Source | -2.12Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 1,147,000,000Source | 1,133,000,000Source | 1,165,000,000Source | 1,147,000,000Source | 1,156,000,000Source | 1,138,000,000Source | 1,145,000,000Source | 1,131,000,000Source | 1,119,000,000Source | 1,110,000,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 1,164,000,000Source | 1,133,000,000Source | 1,165,000,000Source | 1,161,000,000Source | 1,179,000,000Source | 1,159,000,000Source | 1,163,000,000Source | 1,131,000,000Source | 1,119,000,000Source | 1,110,000,000Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 144,000,000Source | 146,000,000Source | 139,000,000Source | 148,000,000Source | 137,000,000Source | 145,000,000Source | 581,000,000Source | 588,000,000Source | 616,000,000Source | 732,000,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 1,094,000,000Source | 333,000,000Source | 430,000,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 249,000,000Source | 259,000,000Source | 241,000,000Source | 251,000,000Source | 239,000,000Source | 244,000,000Source | 1,002,000,000Source | 1,059,000,000Source | 1,153,000,000Source | 1,308,000,000Source |
| General and Administrative ExpenseUSD | — | — | 317,000,000Source | 298,000,000Source | 317,000,000Source | 305,000,000Source | 304,000,000Source | 297,000,000Source | 1,287,000,000Source | 1,161,000,000Source | 1,162,000,000Source | 1,180,000,000Source |
| Goodwill, Impairment LossUSD | — | — | 0Source | 600,000,000Source | — | 0Source | — | — | 0Source | 1,280,000,000Source | 700,000,000Source | 2,045,000,000Source |
| Gross ProfitUSD | — | — | 2,304,000,000Source | 2,148,000,000Source | 2,153,000,000Source | 2,102,000,000Source | 1,972,000,000Source | 1,877,000,000Source | 8,938,000,000Source | 8,064,000,000Source | 7,645,000,000Source | 6,973,000,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -225,000,000Source | -456,000,000Source | -767,000,000Source | -119,000,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | 2,000,000Source | 3,000,000Source | — | -1,000,000Source | -1,000,000Source | — | 15,000,000Source | 1,000,000Source | 2,000,000Source | 21,000,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | 916,000,000Source | 1,002,000,000Source | 1,029,000,000Source | 930,000,000Source |
| Nonoperating Income (Expense)USD | — | — | -237,000,000Source | -272,000,000Source | -224,000,000Source | -252,000,000Source | -216,000,000Source | -225,000,000Source | -934,000,000Source | -981,000,000Source | -1,057,000,000Source | -966,000,000Source |
| Other IncomeUSD | — | — | — | — | — | — | — | — | — | — | 49,000,000Source | 107,000,000Source |
| Other Operating Income (Expense), NetUSD | — | — | -7,000,000Source | 21,000,000Source | 19,000,000Source | -4,000,000Source | 9,000,000Source | -5,000,000Source | -18,000,000Source | 14,000,000Source | 49,000,000Source | 107,000,000Source |
| Research and Development ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 98,000,000Source |
| Selling and Marketing ExpenseUSD | — | — | 656,000,000Source | 626,000,000Source | 717,000,000Source | 654,000,000Source | 696,000,000Source | 622,000,000Source | 2,686,000,000Source | 2,541,000,000Source | 2,336,000,000Source | 2,265,000,000Source |
Filing attachments
d155511dex42.htm · 8-K · 2026-09-16
EX-4.2 2 d155511dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 TEVA PHARMACEUTICAL FINANCE NETHERLANDS II B.V., as Issuer, TEVA PHARMACEUTICAL INDUSTRIES LIMITED, as Guarantor, THE BANK OF NEW YORK MELLON, as Trustee and THE BANK OF NEW YORK MELLON, LONDON BRANCH, as Paying Agent SIXTH SUPPLEMENTAL SENIOR INDENTURE Dated as of September 16, 2026 to the Senior Indenture dated as of March 14, 2018 Creating the series of Securities (as defined herein) designated 4.250% Senior Notes due 2033…
Read attachment ↗d155511dex44.htm · 8-K · 2026-09-16
EX-4.4 3 d155511dex44.htm EX-4.4 EX-4.4 Exhibit 4.4 TEVA PHARMACEUTICAL FINANCE NETHERLANDS III B.V., as Issuer, TEVA PHARMACEUTICAL INDUSTRIES LIMITED, as Guarantor, and THE BANK OF NEW YORK MELLON, as Trustee SIXTH SUPPLEMENTAL SENIOR INDENTURE Dated as of September 16, 2026 to the Senior Indenture dated as of March 14, 2018 Creating the series of Securities (as defined herein) designated 5.500% Senior Notes due 2034 and 5.750% Senior Notes due 2037 Table of Contents …
Read attachment ↗d155511dex46.htm · 8-K · 2026-09-16
EX-4.6 4 d155511dex46.htm EX-4.6 EX-4.6 Exhibit 4.6 TEVA PHARMACEUTICAL FINANCE NETHERLANDS IV B.V., as Issuer, TEVA PHARMACEUTICAL INDUSTRIES LIMITED, as Guarantor, and THE BANK OF NEW YORK MELLON, as Trustee SECOND SUPPLEMENTAL SENIOR INDENTURE Dated as of September 16, 2026 to the Senior Indenture dated as of May 28, 2025 Creating the series of Securities (as defined herein) designated 5.250% Senior Notes due 2032 TABLE OF CONTENTS …
Read attachment ↗d81245dex991.htm · 8-K · 2026-09-11
EX-99.1 3 d81245dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes TEL AVIV, Israel, September 10, 2026 (GLOBE NEWSWIRE) - Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it successfully priced its offering of approximately $4.9 billion (equivalent) of senior notes (the “Notes”). Teva expects to use the net proceeds from the offering, together with cash on hand, (i) to fund the redempt…
Read attachment ↗d153033dex991.htm · 8-K · 2026-09-03
Exhibit 99.1 Explanatory Note Teva Pharmaceutical Industries Limited (“Teva” or the “Company”) is filing this Exhibit 99.1 to recast historical segment information as set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission (“SEC”) on February 3, 2026 (the “Original Report”). As previously disclosed and as reflected in the Original Report, in alignment with Teva’s Pivot to Growth strategy, commencing Jan…
Read attachment ↗d174614dex41.htm · 8-K · 2026-09-03
Exhibit 4.1 Execution Version TEVA PHARMACEUTICAL INDUSTRIES LIMITED and CITIBANK, N.A., as Depositary, and ALL HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES OUTSTANDING UNDER THE TERMS OF THE SECOND AMENDED AND RESTATED DEPOSIT AGREEMENT, DATED AS OF DECEMBER 4, 2018 Amendment No. 1 to Second Amended and Restated Deposit Agreement Dated as of August 31, 2026 Table of Contents Page ARTICLE…
Read attachment ↗